Biotech's best startups of 2026: Meet this year's Endpoints 11
The Endpoints 11 awards are our chance to tell a story about where biotech is going. In some ways, biotech feels like it has finally emerged from years of uncertainty. The money that fuels the ...
The Endpoints 11 awards, held in Boston, offer insight into the future direction of the biotech industry. Over the past years, biotech has experienced a resurgence in funding and innovation. However, the industry's path ahead remains less predictable due to emerging shifts in power dynamics, the increasing influence of AI, growing influence from China, and the rise of new companies.
This year's list of 11 startups showcases a diverse range of novel approaches in biotech, including gene therapy, CAR-T, oncology, cardiology, longevity, AI, robotics, and unconventional drug development methods. A panel of Endpoints News journalists spent considerable time researching and discussing the most promising candidates to compile this year's list.
The 11 companies on the list include Anew Labs, Azalea Therapeutics, Corsera Health, K2 Therapeutics, Kali Therapeutics, Medici Therapeutics, Medra, NewLimit, SonoThera, Stipple Bio, and Vivodyne. The awards ceremony highlighted the innovative bets these companies are making in the biotech sector. While some of these startups may face challenges, succeed in securing deals with pharmaceutical companies, or receive an IPO or sale, others might not achieve the same level of success.
Despite the inherent risks, the Endpoints News team has a history of identifying promising ideas and teams. They will continue to closely monitor these startups to observe their progress in the coming years.
Written by urgent.news from Endpoints News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
